Alibaba has officially announced a new share issuance, with a placement size of HK$80 billion, representing approximately 4% of its total market capitalization. The offering comes with a discount ranging from 3.6% to 9%, marking one of the few new share sales in the company's history and its largest fundraising effort in recent years.

Placement Scale and Pricing Details

The placement is valued at HK$80 billion, equivalent to roughly 4% of the company's market cap. The discount is set at 3.6% based on last week's US-listed ADR closing price of $119.34, while it expands to approximately 9% when calculated against the Hong Kong closing price of HK$123. In the context of recent AI-sector fundraising in Hong Kong, comparable cases include Zhipu and MiniMax, which offered discounts of 13% and 9.9% respectively. The current placement discount is therefore considered to be within a reasonable range.

A Look Back at Alibaba's Financing History

Notably, this marks one of the very few new share issuances in Alibaba's corporate history, with only two IPOs previously recorded. It also represents the largest financing scale seen in recent years. Over the past three years, the company's fundraising activities have included a $5 billion convertible bond issuance in May 2024, a combination of USD and panda bonds worth approximately $5 billion in November 2024, a zero-coupon exchangeable bond of HK$12 billion backed by ALI HEALTH (00241.HK) shares in July 2025, and a $3.2 billion convertible bond in September 2025. The current financing size closely aligns with market estimates of Alibaba's potential funding gap over the next three years. Additionally, over the past several years, Alibaba has reduced its share count by approximately 15% through buybacks and cancellations.

Share Price Performance and Future Outlook

Excluding the July 2025 financing, which primarily impacted the share price of ALI HEALTH, historical patterns show that one day prior to the May 2024 financing, shares fell 4%, followed by a 2% drop the next day. For the November 2024 financing, the share price declined 2% the day before, but rose 0.8% on the announcement day. In September 2025, shares surged 5.2% on the day the financing was completed. From a sentiment perspective, the ADR has already priced in this development in advance, making this announcement a case of the negative news being largely settled from a trading standpoint. Looking ahead, the May 2024 and November 2024 events marked the starting points of major cycles, while September 2025 represented a short-term peak. The medium-to-long-term trajectory will ultimately depend on broader market sentiment.